Metabolic Disorders in Chronic Lung Diseases

Papaioannou, Ourania; Karampitsakos, Theodoros; Barbayianni, Ilianna; Chrysikos, Serafeim; Xylourgidis, Nikos; Tzilas, Vasilios; Bouros, Demosthenes; Aidinis, Vassilis; Tzouvelekis, Argyrios

doi:10.3389/fmed.2017.00246

Cited by 32 publications

(18 citation statements)

References 129 publications

(144 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Obesity may be due to limited activity in ILD patients, a condition that leads to progressive reduction in exercise tolerance as it becomes more severe (21). Alternatively, and perhaps most intriguingly, it may lend support to the hypothesis that severe ILD is part of the 'metabolic syndrome' (22). This analysis also assessed respiratory support offered to patients hospitalised with ILD.…”

Section: Discussionmentioning

confidence: 99%

Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.

Drake

Docherty

Quint

et al. 2020

Preprint

View full text Add to dashboard Cite

Rationale: The impact of COVID-19 on patients with Interstitial Lung Disease (ILD) has not been established. Objectives: To assess outcomes following COVID-19 in patients with ILD versus those without in a contemporaneous age, sex and comorbidity matched population. Methods: An international multicentre audit of patients with a prior diagnosis of ILD admitted to hospital with COVID-19 between 1 March and 1 May 2020 was undertaken and compared with patients, without ILD obtained from the ISARIC 4C cohort, admitted with COVID-19 over the same period. The primary outcome was survival. Secondary analysis distinguished IPF from non-IPF ILD and used lung function to determine the greatest risks of death. Measurements and Main Results: Data from 349 patients with ILD across Europe were included, of whom 161 were admitted to hospital with laboratory or clinical evidence of COVID-19 and eligible for propensity-score matching. Overall mortality was 49% (79/161) in patients with ILD with COVID-19. After matching ILD patients with COVID-19 had higher mortality (HR 1.60, Confidence Intervals 1.17-2.18 p=0.003) compared with age, sex and co-morbidity matched controls without ILD. Patients with a Forced Vital Capacity (FVC) of <80% had an increased risk of death versus patients with FVC ≥80% (HR 1.72, 1.05-2.83). Furthermore, obese patients with ILD had an elevated risk of death (HR 1.98, 1.13−3.46). Conclusions: Patients with ILD are at increased risk of death from COVID-19, particularly those with poor lung function and obesity. Stringent precautions should be taken to avoid COVID-19 in patients with ILD.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.

Drake

Docherty

Quint

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Recent studies on the pathophysiology of IPF suggest that early alveolar injury activates abnormal alveolar epithelial cells and stimulates the release of mediators including matrix metalloproteinases and TGF beta-1 ( 2 , 58 – 61 ). These mediators activate cytokines and chemokines including IL-1 and IL-13 leading to the phenotype of abnormal wound healing ( 62 – 65 ).…”

Section: Preclinical Studiesmentioning

confidence: 99%

Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis

et al. 2018

Self Cite

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive lung disease of unknown origin. Prognosis is poor, with limited treatment options available, and the median survival remains just 3–5 years. Despite the use of pirfenidone and nintedanib for the treatment of IPF, curative therapies remain elusive and mortality remains high. Regenerative medicine and the use of cell-based therapies has recently emerged as a potential option for various diseases. Promising results of preclinical studies using mesenchymal stem cells (MSCs) suggest that they may represent a potential therapeutic option for the treatment of chronic lung diseases including IPF. Encouraging results of Phase 1 studies of MSCs various have reduced safety concerns. Nonetheless, there is still a pressing need for exploratory biomarkers and interval end-points in the context of MSCs investigation. This review intends to summarize the current state of knowledge for stem cells in the experimental and clinical setting of IPF, present important safety and efficacy issues, highlight future challenges and address the need for large, multicenter clinical trials coupled with realistic end-points, including biomarkers, to assess treatment efficacy.

show abstract

“…In this review, we provide an overview of how metabolomics has been used to further the understanding of CLD, as well as present some of the metabolic pathways that have been investigated in COPD, asthma and idiopathic pulmonary fibrosis (IPF). This study builds on the existing work of Papaioannou et al and Zhao et al who reviewed global metabolic changes in patients with CLD. In addition to a critical assessment of published outcomes, our review seeks to examine the experimental approaches and instrumental parameters used in these studies, as well as provide some insight into the emerging trends of metabolomic‐driven biomarker discovery.…”

Section: Introductionmentioning

confidence: 96%

“…Chronic lung diseases (CLD) are complex, progressive disorders with increasing incidence and mortality . Chronic obstructive pulmonary disease (COPD), asthma and pulmonary fibrosis are examples of chronic lung conditions that can significantly impact the quality of life . The management of such conditions can be greatly enhanced using personalized approaches to direct treatment.…”

Section: Introductionmentioning

confidence: 99%

Metabolomics in chronic lung diseases

et al. 2019

View full text Add to dashboard Cite

Chronic lung diseases represent a significant global burden. Their increasing incidence and complexity render a comprehensive, multidisciplinary and personalized approach to each patient, critically important. Most recently, unique biochemical pathways and disease markers have been identified through large‐scale metabolomic studies. Metabolomics is the study of metabolic pathways and the measurement of unique biomolecules in a living system. Analysing samples from different compartments such as bronchoalveolar lavage fluid (BALF) and plasma has proven useful for the characterization of a number of pathological conditions and offers promise as a clinical tool. For example, several studies using mass spectrometry (MS) have shown alterations in the sphingolipid metabolism of chronic obstructive pulmonary disease (COPD) sufferers. In this article, we present a practical review of the application of metabolomics to the study of chronic lung diseases (CLD): COPD, idiopathic pulmonary fibrosis (IPF) and asthma. The insights, which the analytical strategies employed in metabolomics, have provided to the dissection of the biochemistry of CLD and future clinical biomarkers are explored.

show abstract

Metabolic Disorders in Chronic Lung Diseases

Cited by 32 publications

References 129 publications

Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.

Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.

Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis

Metabolomics in chronic lung diseases

Contact Info

Product

Resources

About